Skip to main content
SpringerLink
Log in

Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Dopamine agonists are effective treatments for a variety of indications, including Parkinson’s disease and restless legs syndrome, but may have serious side effects, such as orthostatic hypotension, hallucinations, and impulse control disorders (including pathological gambling, compulsive eating, compulsive shopping/buying, and hypersexuality). The most effective way to alleviate these side effects is to taper or discontinue dopamine agonist therapy. A subset of patients who taper a dopamine agonist, however, develop dopamine agonist withdrawal syndrome (DAWS), which has been defined as a severe, stereotyped cluster of physical and psychological symptoms that correlate with dopamine agonist withdrawal in a dose-dependent manner, cause clinically significant distress or social/occupational dysfunction, are refractory to levodopa and other dopaminergic medications, and cannot be accounted for by other clinical factors. The symptoms of DAWS include anxiety, panic attacks, dysphoria, depression, agitation, irritability, suicidal ideation, fatigue, orthostatic hypotension, nausea, vomiting, diaphoresis, generalized pain, and drug cravings. The severity and prognosis of DAWS is highly variable. While some patients have transient symptoms and make a full recovery, others have a protracted withdrawal syndrome lasting for months to years, and therefore may be unwilling or unable to discontinue DA therapy. Impulse control disorders appear to be a major risk factor for DAWS, and are present in virtually all affected patients. Thus, patients who are unable to discontinue dopamine agonist therapy may experience chronic impulse control disorders. At the current time, there are no known effective treatments for DAWS. For this reason, providers are urged to use dopamine agonists judiciously, warn patients about the risks of DAWS prior to the initiation of dopamine agonist therapy, and follow patients closely for withdrawal symptoms during dopamine agonist taper.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev. 2008;2:CD006564.

    PubMed  Google Scholar 

  2. Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson’s disease. Neurodegener Dis. 2013;11(2):63–71.

    Article  PubMed  CAS  Google Scholar 

  3. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295–310.

    Article  PubMed  CAS  Google Scholar 

  4. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.

    Article  PubMed  Google Scholar 

  5. Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. 2009;25(3):425–31.

    Article  PubMed  Google Scholar 

  6. Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179–81.

    Article  PubMed  CAS  Google Scholar 

  7. Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.

    Article  PubMed  CAS  Google Scholar 

  8. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30(5):249–55.

    Article  PubMed  CAS  Google Scholar 

  9. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524–9.

    Article  PubMed  Google Scholar 

  10. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology. 2003;61(3):422–3.

    Article  PubMed  CAS  Google Scholar 

  11. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.

    Article  PubMed  Google Scholar 

  12. Sadock BJ, Kaplan HI, Sadock VA. Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Wolter Kluwer/Lippincott Williams & Wilkins; 2007.

  13. Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130–5.

    Article  PubMed  Google Scholar 

  14. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–33.

    Google Scholar 

  15. Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, et al. Addiction-like manifestations and Parkinson’s disease: a large single center 9-year experience. Int J Neurosci. 2012;122(3):145–53.

    Article  PubMed  CAS  Google Scholar 

  16. Nirenberg MJ. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson’s disease surgery. Brain. 2010;133(11):e155. author reply e6.

    Google Scholar 

  17. Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(9):1051–2.

    Article  PubMed  Google Scholar 

  18. Dorfman BJ, Nirenberg MJ. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism Relat Disord. 2013;19(2):269–70.

    Article  PubMed  Google Scholar 

  19. Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(4):377–81.

    Article  PubMed  Google Scholar 

  20. MacMahon MJ, MacMahon DG. Management of Parkinson’s disease in the acute hospital environment. J R Coll Physicians Edinb. 2012;42(2):157–62.

    PubMed  CAS  Google Scholar 

  21. Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today (Barc). 2010;46(7):483–505.

    Article  CAS  Google Scholar 

  22. Schupbach M, Gargiulo M, Welter ML, Mallet L, Behar C, Houeto JL, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology. 2006;66(12):1811–6.

    Article  PubMed  CAS  Google Scholar 

  23. Gilbert F. The burden of normality: from ‘chronically ill’ to ‘symptom free’. New ethical challenges for deep brain stimulation postoperative treatment. J Med Ethics. 2012;38(7):408–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The author reports no conflict of interest and no financial support related to the content of the manuscript.

Author information

Authors and Affiliations

  1. Department of Neurology, NYU School of Medicine, New York, NY, USA

    Melissa J. Nirenberg

  2. NYU Parkinson’s and Movement Disorders Center, 145 East 32nd Street, 2nd Floor, New York, NY, 10016, USA

    Melissa J. Nirenberg

Authors
  1. Melissa J. Nirenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melissa J. Nirenberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nirenberg, M.J. Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care. Drugs Aging 30, 587–592 (2013). https://doi.org/10.1007/s40266-013-0090-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0090-z

Keywords

Search

Navigation